Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion

Autor:	Andrew T. Hattersley, Bernard Thorens
Jazyk:	angličtina
Rok vydání:	2015
Předmět:	medicine.medical_specialty Glucagon Alpha cell chemistry.chemical_compound Sodium-Glucose Transporter 1 Glucosides Sodium-Glucose Transporter 2 Internal medicine Benzhydryl Compounds/pharmacology Diabetes Mellitus Type 2/drug therapy Diabetes Mellitus Type 2/metabolism Glucagon/secretion Glucagon-Secreting Cells/metabolism Glucose/metabolism Glucosides/pharmacology Humans Sodium-Glucose Transporter 1/metabolism Sodium-Glucose Transporter 2/antagonists & inhibitors Sodium-Glucose Transporter 2/metabolism medicine Dapagliflozin Benzhydryl Compounds Sodium-Glucose Transporter 2 Inhibitors Kidney Reabsorption business.industry Glucose transporter General Medicine 3. Good health Renal glucose reabsorption medicine.anatomical_structure Endocrinology Glucose chemistry Diabetes Mellitus Type 2 Glucagon-Secreting Cells business
Zdroj:	New England Journal of Medicine, vol. 373, no. 10, pp. 974-976 New England Journal of Medicine
Popis:	Dapagliflozin targets the sodium-coupled glucose transporter type 2 in the renal proximal tubule, preventing the reabsorption of glucose into the blood. It also has a direct effect on the islet alpha cell, which may counter its effect on glucose reabsorption in the kidney.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48e7151acd5054c3a1711d236ea76a9c https://serval.unil.ch/resource/serval:BIB_DA645CAAB37A.P001/REF.pdf Zobrazit plný text záznamu